MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24 Share Price

DE000ME4N394

Real-time Bid/Ask 14:08:04 02/07/2024 BST
0.72 ^EUR / 0.74 ^EUR	+5.80%

Current month	-6.76%
1 month	+23.21%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/410/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02:26pm	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02:15pm	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	01:34pm	BU
Vertex to Announce Second Quarter 2024 Financial Results on August 1	07-01	BU

More news

Quotes 5-day view

Date	Price	Change
02/07/24	0.72	+4.35%
01/07/24	0.69	-6.76%
28/06/24	0.74	+1.37%
27/06/24	0.73	+1.39%
26/06/24	0.72	0.00%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 12:59 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N39
ISIN	DE000ME4N394
Date issued	05/12/2023
Strike	410 $
Maturity	20/09/2024 (80 Days)
Parity	100 : 1
Emission price	0.23 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.84 €
Lowest since issue	0.219 €
Delta	0.8x
Omega	4.849
Premium	3.51x
Gearing	6.06x
Moneyness	1.149
Difference Strike	-59.77 $
Difference Strike %	-14.58%
Spread	0.01 €
Spread %	1.37%
Theoretical value	0.7400
Implied Volatility	46.05 %
Total Loss Probability	27.70 %
Intrinsic value	0.5708
Present value	0.1692
Break even	489.41 €
Theta	-0.01x
Vega	0.01x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus